-
Nicotine Lozenges, Tobacco-Free Snuff Help Smokeless Tobacco Users Quit, Mayo Clinic Finds
Share this:
ROCHESTER, Minn. — Smokeless tobacco users who said they didn't want to quit changed their minds or significantly cut back when given nicotine lozenges or tobacco-free snuff in a Mayo Clinic study. The findings are published in the February issue of Addictive Behaviors.
MULTIMEDIA ALERT: Video and audio of Jon Ebbert, M.D., will be available for download on the Mayo Clinic News Network.
Mayo researchers recruited 81 users of chewing tobacco or snuff with no intention of quitting in the next 30 days. Forty were given 4-mg nicotine lozenges and 41 received tobacco-free snuff to help cut back their smokeless tobacco use. They were asked to cut back 50 percent by one month and 75 percent by two months.
Participants received eight weeks of treatment and behavioral counseling on tobacco reduction strategies with follow-up to 26 weeks. Both groups significantly reduced smokeless tobacco use in cans used per week and dips per day and sustained it through the end of the study. About one-third of study participants continued using 75 percent less smokeless tobacco use 26 weeks after the study, and 12 percent of the participants quit using it completely.
"The reason why that is so striking and important to us is these patients had no intention of quitting," says addiction expert Jon Ebbert, M.D., a tobacco researcher at the Mayo Clinic Nicotine Dependence Center. "Through the process of just reducing their tobacco, participants wanted to quit and were successful in doing so."
Long-term smokeless tobacco use is associated with cardiovascular disease and cancer. Previous studies have evaluated the effectiveness of nicotine lozenges and tobacco-free snuff for reducing smokeless tobacco use among smokeless tobacco users not ready to quit, but no comparative effectiveness trials of these two products have been conducted, Dr. Ebbert says.
The study was funded by the National Cancer Institute (R01 CA121165).
Share this:
Related articles
ROCHESTER, Minn. — Researchers from Mayo Clinic Comprehensive Cancer Center and Mayo Clinic Center for Individualized Medicine have discovered new genetic markers to identify Lynch ...
ROCHESTER, Minn. — Survival outcomes using chimeric antigen receptor-T cell therapy (CAR-T cell therapy) continue to be impressive for patients with some blood cancers. “Five years ...
ROCHESTER, Minn. — In a randomized trial, published in The Lancet Oncology, Mayo Clinic Comprehensive Cancer Center researchers uncover evidence supporting a shorter treatment time ...